This report describes the synthesis and biological evaluation of cationic (99m)Tc-tricarbonyl complexes anchored by ether-containing tris(pyrazolyl)methane or bis(pyrazolyl)ethanamine ligands to be applied in the design of radiopharmaceuticals for myocardial imaging: fac-[(99m)Tc(CO)(3){RC(pz)(3)}](+) (R = H (1a), MeOCH(2) (2a), EtOCH(2) (3a), (n)PrOCH(2) (4a)) and fac-[(99m)Tc(CO)(3){RNHCH(2)CH(pz)(2)}](+) (R = H (5a), MeO(CH(2))(2) (6a)) (pz = pyrazolyl). At the no carrier added level, complexes 1a-6a were obtained in high radiochemical yield (> 98%) by reaction of fac-[(99m)Tc(CO)(3)(H(2)O)(3)](+) with the corresponding tripod chelator in aqueous medium. All these complexes display a high in vitro and in vivo stability, except 6a which metabolizes in vivo yielding fac-[(99m)Tc(CO)(3){HO(CH(2))(2)NHCH(2)CH(pz)(2)}](+) (7a). Biological studies in mice have shown that among the radiotracers evaluated in this work, 3a, anchored by a tris(pyrazolyl)methane chelator bearing an ethyl methyl ether substituent, has the highest heart uptake (3.6 +/- 0.5%ID g(-1) at 60 min p.i.). Complex 3a presents also the best heart: blood, heart: liver and heart: lung ratios, appearing as the most promising as a potential myocardial imaging agent. The chemical identity of 1a-7a was ascertained by HPLC comparison with the previously reported fac-[Re(CO)(3){HC(pz)(3)}]Br (1) and with the novel fac-[Re(CO)(3){RC(pz)(3)}]Br (R = MeOCH(2) (2), EtOCH(2) (3), (n)PrOCH(2)(4)) and fac-[Re(CO)(3){RNHCH(2)CH(pz)(2)}]Br (R = H (5), MeO(CH(2))(2) (6) HO(CH(2))(2) (7)). The novel Re(I) tricarbonyl complexes, 2-7, were characterized by the common analytical techniques, including single crystal X-ray diffraction analysis. The solid state structure confirmed the presence of facial and tridentate (kappa(3)-N(3)) anchor ligands. Solution NMR studies have also shown that this kappa(3)-N(3) coordination mode is retained in solution for all complexes (2-7).
The novel trihydro(mercaptoazolyl)borates Na[H(3)B(tim(Me))] (L(1)) (tim(Me) = 2-mercapto-1-methylimidazolyl), Na[H(3)B(tim(Bupip))] (L(2)) (tim(Bupip) = 1-[4-((2-methoxyphenyl)-1-piperazinyl)butyl]-2-mercaptoimidazolyl), and Na[H(3)B(bzt)] (L(3)) (bzt = 2-mercaptobenzothiazolyl) were synthesized by reaction of NaBH(4) with the corresponding azole. Ligands L(1)-L(3) represent a new class of light and soft scorpionates that stabilizes the [M(CO)(3)](+) core (M = (99)Tc, Re) by formation of the complexes fac-[M{kappa(3)-H(mu-H)(2)B(tim(Me))}(CO)(3)] (M = (99)Tc (1), Re (2)), fac-[Re{kappa(3)-H(mu-H)(2)B(tim(Bupip))}(CO)(3)] (3), and fac-[Re{kappa(3)-H(mu-H)(2)B(bzt)}(CO)(3)] (4), respectively. The soft scorpionates are coordinated to the metal in unique (kappa(3)-H, H', S) fashion, as confirmed by X-ray crystallography of 1, 2, and 4. These complexes with bis-agostic hydride coordination are formed in aqueous solution with the two hydrides replacing two coordinating aquo ligands. The agostic hydrogen atoms were located directly, confirming an unprecedented donor atom set combining one sulfur and two hydrogen atoms. Preliminary studies have shown the possibility of preparing some of these complexes at the no carrier added level ((99m)Tc), under conditions as required in radiopharmaceutical preparation. Due to their lipophilicity, small-size, and easy functionalization with adequate biomolecules, the trihydro(mercaptoazolyl)borate technetium tricarbonyl complexes are suitable for the design of CNS receptor ligand radiopharmaceuticals as exemplified with 3, comprising a pendant serotonergic 5-HT(1A) ligand. The integrated design of radiopharmaceuticals involving a bis-agostic scorpionate ligand is demonstrated by the synthesis of 4, with an integrated benzothiazolyl fragment for the recognition of beta-amyloid plaques.
Aiming to develop new bone-seeking radiotracers based on the organometallic core fac-[(99m)Tc(CO)(3)](+) with improved radiochemical and biological properties, we have prepared new conjugates with phosphonate pendant groups. The conjugates comprise a chelating unit for metal coordination, which corresponds to a pyrazolyl-containing backbone (pz) with a N,N,N donor-atom set, and a pendant diethyl phosphonate (pz-MPOEt), phosphonic acid (pz-MPOH) or a bisphosphonic acid (pz-BPOH) group for bone targeting. Reactions of the conjugates with the precursor [(99m)Tc(H(2)O)(3)(CO)(3)](+) yielded (mote than 95%) the single and well-defined radioactive species [(99m)Tc(CO)(3)(kappa(3)-pz-MPOEt)](+) (1a), [(99m)Tc(CO)(3)(kappa(3)-pz-MPOH](+) (2a) and [(99m)Tc(CO)(3)(kappa(3)-pz-BPOH)](+) (3a), which were characterized by reversed-phase high-performance liquid chromatography . The corresponding Re surrogates (1-3), characterized by the usual analytical techniques, including X-ray diffraction analysis in the case of 1, allowed for macroscopic identification of the radioactive conjugates. These radioactive complexes revealed high stability both in vitro (phosphate-buffered saline solution and human plasma) and in vivo, without any measurable decomposition. Biodistribution studies of the complexes in mice indicated a fast rate of blood clearance and high rate of total radioactivity excretion, occurring primarily through the renal-urinary pathway in the case of complex 3a. Despite presenting moderate bone uptake (3.04 +/- 0.47% injected dose per gram of organ, 4 h after injection), the high stability presented by 3a and its adequate in vivo pharmacokinetics encourages the search for new ligands with the same chelating unit and different bisphosphonic acid pendant arms.
The homoleptic compounds [U(salan-R2)2] (R = Me (1), tBu (2)) were prepared in high yield by salt-metathesis reactions between UI4(L)2 (L = Et2O, PhCN) and 2 equiv of [K2(salan-R2)] in THF. In contrast, the reaction of the tetradentate ligands salan-R2 with UI3(THF)4 leads to disproportionation of the metal and to mixtures of U(IV) [U(salan-R2)2] and [U(salan-R2)I2] complexes, depending on the ligand to M ratio. The reaction of K2salan-Me2 ligand with U(IV) iodide and chloride salts always leads to mixtures of the homoleptic bis-ligand complex [U(salan-Me2)2] and heteroleptic complexes [U(salan-Me2)X2] in different organic solvents. The structure of the heteroleptic complex [U(salan-Me2)I2(CH3CN)] (4) was determined by X-ray studies. Heteroleptic U(IV) and Th(IV) chloride complexes were obtained in good yield using the bulky salan-tBu2 ligand. The new complexes [U(salan-tBu2)Cl2(bipy)] (5) and [Th(salan-tBu2)Cl2(bipy)] (8) were crystallographically characterized. The salan-tBu2 halide complexes of U(IV) and Th(IV) revealed good precursors for the synthesis of stable dialkyl complexes. The six-coordinated alkyl complexes [Th(salan-tBu2)(CH2SiMe3)2] (9) and [U(salan-tBu2)(CH2SiMe3)2] (10) were prepared by addition of LiCH2SiMe3 to the chloride precursor in toluene, and their solution and solid-state structures (for 9) were determined by NMR and X-ray studies. These complexes are stable for days at room temperature. Preliminary reactivity studies show that CO2 inserts into the An–C bond to afford a mixture of carboxylate products. In the presence of traces of LiCl, crystals of the dimeric insertion product [Th2Cl(salan-tBu2)2(μ-η1:η1-O2CCH2SiMe3)2(μ-η1:η2-O2CCH2SiMe3)] (11) were isolated. The structure shows that CO2 insertion occurs in both alkyl groups and that the resulting carboxylate is easily displaced by a chloride anion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.